New research shows that tirzepatide, the latest FDA-approved obesity drug, really can help people lose substantial amounts of weight—but only if they continue taking it. The study found that people who stopped taking tirzepatide after 36 weeks regained much of their lost weight within a year, while those who continued…
New research shows that tirzepatide, the latest FDA-approved obesity drug, really can help people lose substantial amounts of weight—but only if they continue taking it. The study found that people who stopped taking tirzepatide after 36 weeks regained much of their lost weight within a year, while those who continued…Read more… Read More obesity, eli lilly and company, health medical pharma, semaglutide, glucagon like peptide 1, anti obesity medication, type 2 diabetes, weight loss, tirzepatide, eli lilly and, peptide therapeutics, novo nordisk, diabetes, peptide hormones, eli lilly, hospitality recreation Gizmodo
